• Abbott Laboratories (ABT) Paid CEO More Than Taxes to Uncle Sam More...
• Cipla Medpro Suspends CEO for "Serious" Charges More...
• Myrexis, Inc. Announces Death of Chief Executive Officer Richard B. Brewer, Trailblazing Biotechnology Industry Veteran and Patient Advocate More...
• Forty Year Industry Veteran Randall E. Woods Named CEO at Sophiris Bio More...
• Dr. Harold Schoenhaus Joins the Scientific Advisory Board of Alliqua, Inc. (Formerly known as HepaLife Technologies Inc.) (ALQA) More...
• Fluidigm Corporation Prices $52.2 Million Public Offering of Common Stock More...
• Charles Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy, Creates Itonis Pharmaceuticals, a New Division of Itonis, Inc. More...
• TG Therapeutics, Inc., Rhizen Pharmaceuticals Ink Deal Worth Up to $250 Million More...
• Biogen Idec, Inc. (Massachusetts) (BIIB), Regulus Therapeutics, Inc. Cut Deal to Monitor MS More...
• BioTime (BTX) and OncoCyte Corporation Publish Data on the Gene COL10A1 as a Marker and Potential Diagnostic for a Wide Array of Human Cancers More...
• DARA BioSciences, Inc. Announces Soltamox® Distribution Partnership in the Commonwealth of Puerto Rico More...
• Quotient Biodiagnostics Signs 36 Month Agreement With the Premier Healthcare Alliance to Supply Blood Bank Reagents to Its 2,600 Member Hospitals More...
• Bio-Path Holdings, Inc. (BPTH) Reports Second Quarter 2012 Operational and Financial Results More...
• Genmab A/S (GEN.CO) Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance More...
• Navidea Biopharmaceuticals (NEOP) Announces 2012 Annual Meeting Results More...
• Probi: Lower Second-Quarter Income but Continued Growth for Full-Year 2012 More...
• Perrigo Company (PRGO) Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations More...
• ImmusanT, Inc. Relocates Offices to State-of-the-Art Innovation Facility More...
• Idenix Pharmaceuticals, Inc. (IDIX) Shares Plunge on Hep C Tx Heart Fears More...
• Novartis AG (NVS) Eye Drug Shows Promise in Study More...
• Pfizer Inc. (PFE)'s Experimental Drug Works in Ulcerative Colitis More...
• The New England Journal of Medicine Publishes Results From The New England Journal of Medicine and Medivation, Inc. (MDVN)'s Phase 3 AFFIRM Trial of Enzalutamide More...
• Pluristem Therapeutics (PSTI) Receives Approval From Indian Ministry of Health for Use of PLX Cells in Phase II Trial for Treatment of Buerger's Disease More...
• FDA: Codeine Can be Fatal to Some Children More...
• Pharmalucence, Inc. Announces FDA Approval and Orphan Drug Designation for Use of Sulfur Colloid Injection to Locate Lymph Nodes in Malignant Melanoma Patients More...
• IMPAX Laboratories, Inc. (IPXL) Hopes Parkinson's Drug is a Game Changer More...
• Apexigen Announces the Filing of an IND by its Partner, 3SBio Inc. (SSRX) More...
• Dark Chocolate May Help Lower Blood Pressure, National Institute of Integrative Medicine Study More...
• New Drug Extends Life in Men With Advanced Prostate Cancer Patients, Memorial Sloan-Kettering Cancer Center Study More...
• Babies May Not Have a "Moral Compass" After All, University of Otago Study More...
• Gut Bacteria Linked to Obesity and Metabolic Syndrome Identified, University of Maryland School of Medicine Study More...
• Cipla Medpro Suspends CEO for "Serious" Charges More...
• Myrexis, Inc. Announces Death of Chief Executive Officer Richard B. Brewer, Trailblazing Biotechnology Industry Veteran and Patient Advocate More...
• Forty Year Industry Veteran Randall E. Woods Named CEO at Sophiris Bio More...
• Dr. Harold Schoenhaus Joins the Scientific Advisory Board of Alliqua, Inc. (Formerly known as HepaLife Technologies Inc.) (ALQA) More...
• Fluidigm Corporation Prices $52.2 Million Public Offering of Common Stock More...
• Charles Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy, Creates Itonis Pharmaceuticals, a New Division of Itonis, Inc. More...
• TG Therapeutics, Inc., Rhizen Pharmaceuticals Ink Deal Worth Up to $250 Million More...
• Biogen Idec, Inc. (Massachusetts) (BIIB), Regulus Therapeutics, Inc. Cut Deal to Monitor MS More...
• BioTime (BTX) and OncoCyte Corporation Publish Data on the Gene COL10A1 as a Marker and Potential Diagnostic for a Wide Array of Human Cancers More...
• DARA BioSciences, Inc. Announces Soltamox® Distribution Partnership in the Commonwealth of Puerto Rico More...
• Quotient Biodiagnostics Signs 36 Month Agreement With the Premier Healthcare Alliance to Supply Blood Bank Reagents to Its 2,600 Member Hospitals More...
• Bio-Path Holdings, Inc. (BPTH) Reports Second Quarter 2012 Operational and Financial Results More...
• Genmab A/S (GEN.CO) Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance More...
• Navidea Biopharmaceuticals (NEOP) Announces 2012 Annual Meeting Results More...
• Probi: Lower Second-Quarter Income but Continued Growth for Full-Year 2012 More...
• Perrigo Company (PRGO) Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations More...
• ImmusanT, Inc. Relocates Offices to State-of-the-Art Innovation Facility More...
• Idenix Pharmaceuticals, Inc. (IDIX) Shares Plunge on Hep C Tx Heart Fears More...
• Novartis AG (NVS) Eye Drug Shows Promise in Study More...
• Pfizer Inc. (PFE)'s Experimental Drug Works in Ulcerative Colitis More...
• The New England Journal of Medicine Publishes Results From The New England Journal of Medicine and Medivation, Inc. (MDVN)'s Phase 3 AFFIRM Trial of Enzalutamide More...
• Pluristem Therapeutics (PSTI) Receives Approval From Indian Ministry of Health for Use of PLX Cells in Phase II Trial for Treatment of Buerger's Disease More...
• FDA: Codeine Can be Fatal to Some Children More...
• Pharmalucence, Inc. Announces FDA Approval and Orphan Drug Designation for Use of Sulfur Colloid Injection to Locate Lymph Nodes in Malignant Melanoma Patients More...
• IMPAX Laboratories, Inc. (IPXL) Hopes Parkinson's Drug is a Game Changer More...
• Apexigen Announces the Filing of an IND by its Partner, 3SBio Inc. (SSRX) More...
• Dark Chocolate May Help Lower Blood Pressure, National Institute of Integrative Medicine Study More...
• New Drug Extends Life in Men With Advanced Prostate Cancer Patients, Memorial Sloan-Kettering Cancer Center Study More...
• Babies May Not Have a "Moral Compass" After All, University of Otago Study More...
• Gut Bacteria Linked to Obesity and Metabolic Syndrome Identified, University of Maryland School of Medicine Study More...
Facebook Inc ( NASDAQ: FB ) stock touched a new all time low $19.72 and keep trading sub $20 levels. For those who have invested on the first day or there after, they have keep loosing their investment values. There was a lot of buzz that Facebook Inc stock might see a steep rise like a fall,but the reality is quite different as stock keep making new lows and toda it has touched an all time low and breaks below with a significant volume. We were recommending a Sell rating on Facebook since an announcement of an IPO and our reason behind this was quite reasonable if you see logically. Don't invest in Facebook stock because you have other value picks available.
The selling in Facebook stock is partly due to the end of lock up period for 270 million shares, that could hit the market over the period of nine months. Read More
The selling in Facebook stock is partly due to the end of lock up period for 270 million shares, that could hit the market over the period of nine months. Read More
Watch the exclusive theatrical trailer of English Vinglish with English subtitles featuring Sridevi who is making her comeback after 14 years. The film is directed by Gauri Shinde & produced by R.Balki. English Vinglish is a tri-lingual movie shot in three languages i.e. Hindi, Tamil & Telugu & is all set for an October release.
The First look of an untitled movie by Yash Chopra ( YRF, Yash Raj Films ) is officially out. It will be starred by Shahrukh Khan, Katrina Kaif and Anushka Sharma and Music by A. R Rahman. Will it be a big romantic block buster? Check out the official first look video by YRF. It will surely lighten up this Diwali as the the king of romance ( Shahrukh Khan ) will again prove his title.Although the name of the movie hasn't announced as we will await the official trailer to be announced soon.
A Yash Chopra Romance |
Anushka Sharma |
Bollywood Town is getting a new auction fever and try to sell everything that can be. After a successful auction of lingerie of Sunny leone, that was worn in Jism 2, Now, Kareena Kapoor is ready for auction of her saree worn in "Halkat Jawani", an item number from movie Heroine.
Our source says, "The money will be donated to a charitable organisation, which Kareena is associated to." There is also news that the Manish Malhotra-designed costume managed to create quite a buzz at the recently concluded Mumbai fashion week.
( Mid-Day )
Watch the official trailer and first look of Halkat Jawaani
Watch the official trailer and first look of Halkat Jawaani
We all like to think we make buying decisions on a rational level, but neuroscientists tell us otherwise. While marketers have known this instinctively, brain mappers have shown that the smallest part of the brain, the amygdala, lights up like a Christmas tree when confronted with fight-or-flight or in this case buy-or-fly situations.
Recently, I visited with Christophe Morin, a French researcher with SalesBrain, which is based in San Francisco and claims to be the world's first neuromarketing agency. His title is chief pain officer. He believes that if a company wants someone to buy its products or services, it must seduce the reptilian brain — the part that controls fear and other emotions.
"Pain" is in his title because his company's approach is to help marketers look at the frustrations and challenges consumers experience. "Humans are pain-avoiding machines," Mr. Morin said. "Sometimes our pain points are conscious and sometimes unconscious."
Six Rules for Small Business
He offered six simple rules that small businesses can follow:
1. Don't use the word "we" or start off your pitch with a corporate overview that lasts 10 minutes. Focus instead on how to relieve your customers' pain. Our brains are extremely self-centered, and we care most about our own survival.
2. About 10,000 messages are sent to our brains daily, so get to the point. "When you sell to the lower brain structure, you must say, 'This is your life with our product or service, this is your life without,'" Mr. Morin said. He cited a successful campaign that helped a client that was selling home flood remediation services to major insurance companies. The campaign featured a traveling exhibit that showed a flooded home and how the company had mastered the art of drying home interiors. "The reptilian brain gets very stimulated by this kind of disruption. Stay away from, "We are one of the leading providers." It's the marketing equivalent of sugar -- empty calories.
3. Make your points visual. Remember the "See and Say" books from childhood? Don't just tell; show. "We are visual people, and the eyes are directly connected to the reptilian brain," he said.
4. Stay concrete and make it tangible. The primal brain isn't able to understand complex language or metaphors. As much as we love word play, if it's too complicated, it doesn't get processed by the parts of us that make decisions. Creating ads with facial expressions is good. "Facial expressions help us decode what people's intentions are," he said.
5. Gain attention quickly in your advertising or marketing and make sure you have a strong close. The brain pays the most attention at the beginning and end of an event. It's important because the brain needs to recap and store.
6. Use emotion. It creates disruption, a contrast with what we expect — surprise, laughter, fear, disgust, anger, it really doesn't matter. If there is emotion, we are more likely to remember the message. Nothing happens in the brain unless some chemical process has found a code to create memories. To create a memorable brand, therefore, you have to use emotional connectors in your advertising. Don't just give your audience the facts, tell them how it will make their lives better and solve their pain.
All in all, Mr. Morin believes that if your target market has to kick your advertising up to their cortex, its not going to be as effective. At our advertising agency, we always encourage clients to let us create advertising that makes that critical emotional connection. Mr. Morin's comments also made me reflect on infomercials. While often considered the bottom feeders of the marketing food chain, infomercials can be effective because they follow these rules: show contrast, keep it simple and be visual.
In May, the Corporate Executive Board, shared research that suggested that brands that help consumers simplify the decision process have customers who are far more likely to purchase their products and recommend them to others. It is a fascinating study that is featured in the Harvard Business Review and states that many businesses are pushing customers away by bombarding them with messaging that is not relevant to how they make decisions.
There has also been much discussion lately about the rewiring that is happening to our brains because of our constant interaction with computers and smartphones. This interaction is further reducing our attention spans, which is pushing overworked and overcommitted American consumers to make purchasing and other decisions more quickly. The upshot is that people want information but they want it baby style — pureed to its most basic and served simply.
Something to wrap your marketing brain around.
Recently, I visited with Christophe Morin, a French researcher with SalesBrain, which is based in San Francisco and claims to be the world's first neuromarketing agency. His title is chief pain officer. He believes that if a company wants someone to buy its products or services, it must seduce the reptilian brain — the part that controls fear and other emotions.
"Pain" is in his title because his company's approach is to help marketers look at the frustrations and challenges consumers experience. "Humans are pain-avoiding machines," Mr. Morin said. "Sometimes our pain points are conscious and sometimes unconscious."
Six Rules for Small Business
He offered six simple rules that small businesses can follow:
1. Don't use the word "we" or start off your pitch with a corporate overview that lasts 10 minutes. Focus instead on how to relieve your customers' pain. Our brains are extremely self-centered, and we care most about our own survival.
2. About 10,000 messages are sent to our brains daily, so get to the point. "When you sell to the lower brain structure, you must say, 'This is your life with our product or service, this is your life without,'" Mr. Morin said. He cited a successful campaign that helped a client that was selling home flood remediation services to major insurance companies. The campaign featured a traveling exhibit that showed a flooded home and how the company had mastered the art of drying home interiors. "The reptilian brain gets very stimulated by this kind of disruption. Stay away from, "We are one of the leading providers." It's the marketing equivalent of sugar -- empty calories.
3. Make your points visual. Remember the "See and Say" books from childhood? Don't just tell; show. "We are visual people, and the eyes are directly connected to the reptilian brain," he said.
4. Stay concrete and make it tangible. The primal brain isn't able to understand complex language or metaphors. As much as we love word play, if it's too complicated, it doesn't get processed by the parts of us that make decisions. Creating ads with facial expressions is good. "Facial expressions help us decode what people's intentions are," he said.
5. Gain attention quickly in your advertising or marketing and make sure you have a strong close. The brain pays the most attention at the beginning and end of an event. It's important because the brain needs to recap and store.
6. Use emotion. It creates disruption, a contrast with what we expect — surprise, laughter, fear, disgust, anger, it really doesn't matter. If there is emotion, we are more likely to remember the message. Nothing happens in the brain unless some chemical process has found a code to create memories. To create a memorable brand, therefore, you have to use emotional connectors in your advertising. Don't just give your audience the facts, tell them how it will make their lives better and solve their pain.
All in all, Mr. Morin believes that if your target market has to kick your advertising up to their cortex, its not going to be as effective. At our advertising agency, we always encourage clients to let us create advertising that makes that critical emotional connection. Mr. Morin's comments also made me reflect on infomercials. While often considered the bottom feeders of the marketing food chain, infomercials can be effective because they follow these rules: show contrast, keep it simple and be visual.
In May, the Corporate Executive Board, shared research that suggested that brands that help consumers simplify the decision process have customers who are far more likely to purchase their products and recommend them to others. It is a fascinating study that is featured in the Harvard Business Review and states that many businesses are pushing customers away by bombarding them with messaging that is not relevant to how they make decisions.
There has also been much discussion lately about the rewiring that is happening to our brains because of our constant interaction with computers and smartphones. This interaction is further reducing our attention spans, which is pushing overworked and overcommitted American consumers to make purchasing and other decisions more quickly. The upshot is that people want information but they want it baby style — pureed to its most basic and served simply.
Something to wrap your marketing brain around.
( The New York Times )
• Ex-Genentech (RHHBY) Staffer Cites Reckless R&D Practices More...
• Icahn Slams Forest Laboratories, Inc. (FRX) Over FDA Warning Letter More...
• Onconova Therapeutics Inc. Logs $50 Million More...
• Kineta Inc. Pulls in $5.8 Million for Autoimmune Drug More...
• Upsher-Smith Laboratories Completes Acquisition of Proximagen Group plc. More...
• Cortex Pharmaceuticals, Inc. (COR) and Pier Pharmaceuticals Consummate Merger More...
• IMS Health (RX) Expands Suite of Syndicated, Web-based Analytics With Acquisition of PharmaDeals Ltd. More...
• Pfizer Inc. (PFE) to Pay $250 Million to AstraZeneca PLC (AZN) for OTC Nexium Marketing Rights More...
• Arrowhead Research Corporation (ARWR) Enters Into Antibody Candidate Evaluation Agreement With Merck & Co., Inc. (MRK) More...
• Plasticell and EMD Millipore Complete Licensing Deal to Distribute Fully Defined, Xeno-Free Mesenchymal Stem Cell Differentiation Media More...
• Bioniche Life Sciences Inc. (BNC) Enters Into an Exclusive U.S. Distribution Agreement for an Equine Product More...
• Zenobia Therapeutics, Inc. Announce a Partnership With the Alzheimer's Drug Discovery Foundation More...
• Dynavax Technologies Corporation (DVAX) AppointsChristine Larson as Chief Financial Officer More...
• ADVENTRX Pharmaceuticals Inc. (ANX) Announces Appointment of Chief Medical Officer More...
• Pharmacyclics, Inc. (PCYC) Appoints Joshua T. BrummExecutive Vice President of Finance More...
• Patheon Inc. (PTI.TO) Announces a Change to Its PDS Management Structure More...
• Array BioPharma, Inc. (ARRY) Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012 More...
• Athersys, Inc. Reports Second Quarter 2012 Results More...
• Bioanalytical Systems, Inc. (BASI) Returns to Profitability Before Restructuring Charges for The Third Quarter Of Fiscal 2012 More...
• Celsion Corporation (CLN) Reports Second Quarter 2012 Financial Results and Business Update More...
• Derma Sciences, Inc. (DSCI) Reports Second Quarter 2012 Financial Results More...
• Shire plc (SHPG) May Leave Wayne to Brace for Potential Expansion More...
• Morphotek Inc. Opening Factory in Exton More...
• FDA Approves New Flu Vaccine for Upcoming Season More...
• Aegerion Pharmaceuticals, Inc. Scores a Date With the FDA More...
• Santarus Inc. (SNTS) Announces FDA Extension of UCERIS New Drug Application Target Action Date to January 16, 2013 More...
• Hemispherx Biopharma (HEB) Release: FDA Accepts Complete Response Submission Regarding the Ampligen® New Drug Application for Chronic Fatigue Syndrome More...
• Biovest International, Inc. Conducts End of Phase III Review With FDA of BiovaxID as Consolidation Therapy in Non-Hodgkin's Lymphoma More...
• Spectrum Pharmaceuticals, Inc. (SPPI) Commences Patient Enrollment in Randomized Phase 2b Clinical Trial of Ozarelix for Hormone-Dependent Prostate Cancer More...
• Coronado Biosciences Initiates Phase 2 Clinical Trial of TSO for the Treatment of Crohn's Disease More...
• Synergy Pharmaceuticals Completes Screening and Planned Enrollment in Phase IIb/III Study in Chronic Idiopathic Constipation Patients More...
• Proteonomix, Inc. (PROT) Receives FDA Permission to Initiate Company-Sponsored Phase 1 Clinical Trial With UMK-121 in Patients with End-Stage Liver Disease More...
• Egg Yolks as Bad as Smoking for Heart, London Health Sciences Centre's University Hospital Study More...
• Snoring in Toddlers Could be Sign of Behavioral Problems, Cincinnati Children's Hospital Medical Center Study More...
• Elderly Brains Get a Boost From Dark Chocolate, University of L'Aquila Study More...
• Why Are People Overconfident So Often? University of Navarra Study More...
• TONIX Pharmaceuticals, Inc. Reports That Sublingual Formulation of Fibromyalgia Drug Reduces Production of a Psychoactive Metabolite, Improving Suitability for Long-Term, Chronic Treatment More...
• OncoNatural Solutions Release: Over-the-Counter Prostate Treatment PHC® Awarded U.S. Patent More...
• Aptalis Pharmaceutical Technologies Announces U.S. Commercial Availability of VIOKACE (Pancrelipase) Tablets More...
• Icahn Slams Forest Laboratories, Inc. (FRX) Over FDA Warning Letter More...
• Onconova Therapeutics Inc. Logs $50 Million More...
• Kineta Inc. Pulls in $5.8 Million for Autoimmune Drug More...
• Upsher-Smith Laboratories Completes Acquisition of Proximagen Group plc. More...
• Cortex Pharmaceuticals, Inc. (COR) and Pier Pharmaceuticals Consummate Merger More...
• IMS Health (RX) Expands Suite of Syndicated, Web-based Analytics With Acquisition of PharmaDeals Ltd. More...
• Pfizer Inc. (PFE) to Pay $250 Million to AstraZeneca PLC (AZN) for OTC Nexium Marketing Rights More...
• Arrowhead Research Corporation (ARWR) Enters Into Antibody Candidate Evaluation Agreement With Merck & Co., Inc. (MRK) More...
• Plasticell and EMD Millipore Complete Licensing Deal to Distribute Fully Defined, Xeno-Free Mesenchymal Stem Cell Differentiation Media More...
• Bioniche Life Sciences Inc. (BNC) Enters Into an Exclusive U.S. Distribution Agreement for an Equine Product More...
• Zenobia Therapeutics, Inc. Announce a Partnership With the Alzheimer's Drug Discovery Foundation More...
• Dynavax Technologies Corporation (DVAX) AppointsChristine Larson as Chief Financial Officer More...
• ADVENTRX Pharmaceuticals Inc. (ANX) Announces Appointment of Chief Medical Officer More...
• Pharmacyclics, Inc. (PCYC) Appoints Joshua T. BrummExecutive Vice President of Finance More...
• Patheon Inc. (PTI.TO) Announces a Change to Its PDS Management Structure More...
• Array BioPharma, Inc. (ARRY) Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012 More...
• Athersys, Inc. Reports Second Quarter 2012 Results More...
• Bioanalytical Systems, Inc. (BASI) Returns to Profitability Before Restructuring Charges for The Third Quarter Of Fiscal 2012 More...
• Celsion Corporation (CLN) Reports Second Quarter 2012 Financial Results and Business Update More...
• Derma Sciences, Inc. (DSCI) Reports Second Quarter 2012 Financial Results More...
• Shire plc (SHPG) May Leave Wayne to Brace for Potential Expansion More...
• Morphotek Inc. Opening Factory in Exton More...
• FDA Approves New Flu Vaccine for Upcoming Season More...
• Aegerion Pharmaceuticals, Inc. Scores a Date With the FDA More...
• Santarus Inc. (SNTS) Announces FDA Extension of UCERIS New Drug Application Target Action Date to January 16, 2013 More...
• Hemispherx Biopharma (HEB) Release: FDA Accepts Complete Response Submission Regarding the Ampligen® New Drug Application for Chronic Fatigue Syndrome More...
• Biovest International, Inc. Conducts End of Phase III Review With FDA of BiovaxID as Consolidation Therapy in Non-Hodgkin's Lymphoma More...
• Spectrum Pharmaceuticals, Inc. (SPPI) Commences Patient Enrollment in Randomized Phase 2b Clinical Trial of Ozarelix for Hormone-Dependent Prostate Cancer More...
• Coronado Biosciences Initiates Phase 2 Clinical Trial of TSO for the Treatment of Crohn's Disease More...
• Synergy Pharmaceuticals Completes Screening and Planned Enrollment in Phase IIb/III Study in Chronic Idiopathic Constipation Patients More...
• Proteonomix, Inc. (PROT) Receives FDA Permission to Initiate Company-Sponsored Phase 1 Clinical Trial With UMK-121 in Patients with End-Stage Liver Disease More...
• Egg Yolks as Bad as Smoking for Heart, London Health Sciences Centre's University Hospital Study More...
• Snoring in Toddlers Could be Sign of Behavioral Problems, Cincinnati Children's Hospital Medical Center Study More...
• Elderly Brains Get a Boost From Dark Chocolate, University of L'Aquila Study More...
• Why Are People Overconfident So Often? University of Navarra Study More...
• TONIX Pharmaceuticals, Inc. Reports That Sublingual Formulation of Fibromyalgia Drug Reduces Production of a Psychoactive Metabolite, Improving Suitability for Long-Term, Chronic Treatment More...
• OncoNatural Solutions Release: Over-the-Counter Prostate Treatment PHC® Awarded U.S. Patent More...
• Aptalis Pharmaceutical Technologies Announces U.S. Commercial Availability of VIOKACE (Pancrelipase) Tablets More...
In Wisconsin, Apple Scores An Early Victory Against Motorola
A recent summary judgement in the Wisconsin chapter of Apple vs. Motorola could set a precedent for patent disputes across the country. On Friday, before Google announced its decision to cut 4,000 jobs at the phone maker, the judge in Wisconsin ruled in a summary judgement that Motorola cannot sue to stop the sale of Apple's patent-flouting devices. Rather, the technology in question ought to be licensable to folks like Apple and Microsoft under fair, reasonable and non-discriminatory, otherwise known as FRAND, terms. Holding Motorola to FRAND terms would also cut down the price that Apple has to pay to license those patents. As Foss Patent explains, this could have an impact on FRAND-related disputes in other places, including the California chapter of Apple vs. Samsung.
Klout Gets An Algorithm And Interface Overhaul
Klout, that score-keeper of online activity, has announced changes to the way it calculates and displays scores and rankings. For one, it will take into account 4 times as many signals, AllThingsD explains, picking up 400 cues like list memberships and Facebook subscriptions before assigning a person a score. Klout's controvertial assigned scores and areas of "influence" have sometimes baffled users in the past, but Klout hopes to make their workings a little more transparent in this update. For one, Klout will indicate in a user's timeline when their influenc-o-meter spikes.
Google+ Joins The Vanity URL Game
Google's revealed that its social network system Google+ is going to allow users to adopt vanity URLs. The move will start with verified people and pages that are mainly celebrities or brands, and then eventually roll out to more users. Currently Google+ user pages are identified by a long string of numbers as an identifier, which is practical but hardly memorable.
Google is following a trail blazed by its more established rivals Twitter and Facebook, which have already adopted a more text-based identifier--Facebook more recently. The use of a simpler user ID allows both brands and named users to stand out a little and may also facilitate discovery of new users and content.
Google's blog posting about the news notes that it will expand to include "many more" users, but doesn't conclusively say that all of the users of the service will be able to choose a short, memorable URL.
A recent summary judgement in the Wisconsin chapter of Apple vs. Motorola could set a precedent for patent disputes across the country. On Friday, before Google announced its decision to cut 4,000 jobs at the phone maker, the judge in Wisconsin ruled in a summary judgement that Motorola cannot sue to stop the sale of Apple's patent-flouting devices. Rather, the technology in question ought to be licensable to folks like Apple and Microsoft under fair, reasonable and non-discriminatory, otherwise known as FRAND, terms. Holding Motorola to FRAND terms would also cut down the price that Apple has to pay to license those patents. As Foss Patent explains, this could have an impact on FRAND-related disputes in other places, including the California chapter of Apple vs. Samsung.
Klout Gets An Algorithm And Interface Overhaul
Klout, that score-keeper of online activity, has announced changes to the way it calculates and displays scores and rankings. For one, it will take into account 4 times as many signals, AllThingsD explains, picking up 400 cues like list memberships and Facebook subscriptions before assigning a person a score. Klout's controvertial assigned scores and areas of "influence" have sometimes baffled users in the past, but Klout hopes to make their workings a little more transparent in this update. For one, Klout will indicate in a user's timeline when their influenc-o-meter spikes.
Google+ Joins The Vanity URL Game
Google's revealed that its social network system Google+ is going to allow users to adopt vanity URLs. The move will start with verified people and pages that are mainly celebrities or brands, and then eventually roll out to more users. Currently Google+ user pages are identified by a long string of numbers as an identifier, which is practical but hardly memorable.
Google is following a trail blazed by its more established rivals Twitter and Facebook, which have already adopted a more text-based identifier--Facebook more recently. The use of a simpler user ID allows both brands and named users to stand out a little and may also facilitate discovery of new users and content.
Google's blog posting about the news notes that it will expand to include "many more" users, but doesn't conclusively say that all of the users of the service will be able to choose a short, memorable URL.
Top Stories
Standard Chartered reaches settlement with N.Y. state
The state of New York has agreed to a $340 million settlement of its case against Standard Chartered. The U.K.-based international bank had been accused of handling $250 billion in Iranian funds in violation of U.S. sanctions against Iran. The settlement will not end U.S. federal agencies' investigations of the bank's dealings with Iran.
India reports sub-7% inflation, but rate outlook is unclear
At 6.9% in July, India's inflation is the lowest it has been since late 2009. Some analysts, however, doubt the reliability of the government figure, noting core inflation was higher even as food prices were reported easing. Forecasts of whether the central bank is now likely to cut rates differed, with some seeing a half-point cut in the near future and others predicting no action.
Indian exports plunge in July
Indian exports were down nearly 15% in July for the sharpest falloff in three years. Commerce Secretary S.R. Rao cited the severe fiscal crisis in the eurozone and slackening demand from the U.S. as contributing factors. Rao said it now will be a "stiff challenge" to achieve the full-year export target of $350 billion.
Second-quarter shrinkage casts gloom over eurozone
The economy of the 17-nation eurozone shrank 0.2% in the second quarter, burdened by budget cuts and the intractable debt crisis. The main problem lies in the struggling economies of the so-called periphery, said Martin Van Vliet, an economist at ING Bank in Amsterdam. "Any recovery will likely remain sluggish and fragile. There are a lot of things that could go wrong on the crisis resolution that could derail the envisaged recovery," Van Vliet said.
Germany tops forecasts with 0.3% growth
Marking a significant departure from the eurozone contraction, Germany's economy grew at a 0.3% pace in the second quarter, topping analysts' estimates. "Positive contributions came from both consumer spending and from net foreign trade," commented Destatis, Germany's statistics office.
France barely avoids a 2nd-quarter contraction
With boosts from the private and public sectors, France's economy narrowly avoided contracting in the second quarter, with no growth. Economists had expected a 0.1% pullback, but the better result allows some room for the government to pare the country's budget deficit.
Struggling Spain posts 2nd month of rising inflation
Despite a deeply mired economy and soaring unemployment, Spain's core consumer inflation rate edged up for the second month in July, to 1.4%. Separately, European Economic and Monetary Affairs Commissioner Olli Rehn suggested that the Spanish government is open to the idea of requesting a sovereign bailout.
With successful debt sale, Greece ensures no August default
Greece ensured it will have enough money next week to repay bonds held by the European Central Bank with a successful debt sale, its largest in two years. About €3.1 billion out of the more than €4 billion raised will repay ECB-held bonds that mature Aug. 20, thus helping Greece avoid default.
U.S. retail sales jump 0.8% in July
Reversing three months of decline, U.S. retail sales jumped 0.8% in July, pointing to a stronger third quarter and indicating that a slowdown in the second quarter may have been temporary. However, signals were mixed in two other indicators, with business inventories rising in June as companies anticipated higher consumer demand but with business sales dropping for the third month in a row.
Stronger-than-expected German growth figures and a surprising jump in U.S. retail sales helped lift European stocks Tuesday, with the Stoxx Europe 600 index adding 0.7%. The same data also provided an early impetus for U.S. shares, but the market eased later in the day and the S&P 500 ended a fraction of a point lower in light trading. Here is a continuously updated list of global stock indexes.
Economic Trends & Outlook
Fears grow that Japanese recovery may be sidetracked
Although the Japanese government is predicting continued recovery over the second half of the year, new concerns are being raised that the imperiled European economy and, domestically, the end of subsidies for eco-friendly vehicles will contribute to further slowing in the current quarter. In addition, poor economic conditions could work to delay implementation of a tax increase just passed into law.
China's 2012 growth is now pegged at 8.0% by Morgan Stanley
An absence of economic stimulus and faltering external demand were cited by Morgan Stanley as it cut its growth forecast for China to 8.0% this year and 8.6% in 2013. Morgan does see an easing policy in the next one to two months, as well as a quarter-point interest-rate cut before the end of the year.
China may be preparing sharper clampdown on property market
With inspection teams back in Beijing and preparing their reports on how well provincial governments have acted to restrain their property markets, expectations are growing that further curbs will be introduced. Some governments have already been warned that they haven't done enough to implement past measures.
South Korea posts 6th month of trade surplus
South Korea's trade surplus in July was down a sharp 40% from the previous month but remained strongly positive at $2.76 billion, according to the Korea Customs Service. July's was the sixth consecutive month of surplus, although exports and imports both declined. Separately, Nomura predicts lower inflation in South Korea for the second half.
National Australia Bank predicts a rate boost in 2013
An increase in interest rates may be in store for the coming year in Australia, according to National Australia Bank, which changed its forecast to become the first major bank predicting a boost. If the central bank does raise its rate, it will mark the first increase since November 2010.
Indonesia consumer confidence, outlook hard to beat
Indonesia's consumer confidence as measured by KADIN-Roy Morgan at 150.5 points in July topped by a wide margin comparable measures in every other Group of 20 country. "While global gloom is taking its toll on China and India, Indonesia continues to swim against the tide," said KADIN Chairman Suryo Sulisto. The survey also found that 79% of Indonesians are optimistic about the country's economy over the next 12 months.
Capital Markets & Financial Products
EU calls for more Indian "stability" to pull in investment
Noting that EU investment to date in China, Russia and other countries far surpasses investment in India, a visiting EU delegation called for more "stability and predictability" in the Indian market. "Though economic relations between India and EU have been multi-dimensional and have expanded over time, they are far below the potential," commented delegate Joao Cravinho. The EU and India are negotiating a trade accord that would lower duties and spur investment.
China's yuan funds for foreign exchange decline amid global slowdown
Reduced trade and foreign direct investment contributed to a decline in China's yuan funds outstanding for foreign exchange in July. The total of 25.66 trillion yuan was down nearly 3.82 billion yuan from the previous month, the central bank said. The drop also suggests a strong outflow of foreign capital amid the global debt crisis and slowing economy.
Standard Chartered reaches settlement with N.Y. state
The state of New York has agreed to a $340 million settlement of its case against Standard Chartered. The U.K.-based international bank had been accused of handling $250 billion in Iranian funds in violation of U.S. sanctions against Iran. The settlement will not end U.S. federal agencies' investigations of the bank's dealings with Iran.
India reports sub-7% inflation, but rate outlook is unclear
At 6.9% in July, India's inflation is the lowest it has been since late 2009. Some analysts, however, doubt the reliability of the government figure, noting core inflation was higher even as food prices were reported easing. Forecasts of whether the central bank is now likely to cut rates differed, with some seeing a half-point cut in the near future and others predicting no action.
Indian exports plunge in July
Indian exports were down nearly 15% in July for the sharpest falloff in three years. Commerce Secretary S.R. Rao cited the severe fiscal crisis in the eurozone and slackening demand from the U.S. as contributing factors. Rao said it now will be a "stiff challenge" to achieve the full-year export target of $350 billion.
Second-quarter shrinkage casts gloom over eurozone
The economy of the 17-nation eurozone shrank 0.2% in the second quarter, burdened by budget cuts and the intractable debt crisis. The main problem lies in the struggling economies of the so-called periphery, said Martin Van Vliet, an economist at ING Bank in Amsterdam. "Any recovery will likely remain sluggish and fragile. There are a lot of things that could go wrong on the crisis resolution that could derail the envisaged recovery," Van Vliet said.
Germany tops forecasts with 0.3% growth
Marking a significant departure from the eurozone contraction, Germany's economy grew at a 0.3% pace in the second quarter, topping analysts' estimates. "Positive contributions came from both consumer spending and from net foreign trade," commented Destatis, Germany's statistics office.
France barely avoids a 2nd-quarter contraction
With boosts from the private and public sectors, France's economy narrowly avoided contracting in the second quarter, with no growth. Economists had expected a 0.1% pullback, but the better result allows some room for the government to pare the country's budget deficit.
Struggling Spain posts 2nd month of rising inflation
Despite a deeply mired economy and soaring unemployment, Spain's core consumer inflation rate edged up for the second month in July, to 1.4%. Separately, European Economic and Monetary Affairs Commissioner Olli Rehn suggested that the Spanish government is open to the idea of requesting a sovereign bailout.
With successful debt sale, Greece ensures no August default
Greece ensured it will have enough money next week to repay bonds held by the European Central Bank with a successful debt sale, its largest in two years. About €3.1 billion out of the more than €4 billion raised will repay ECB-held bonds that mature Aug. 20, thus helping Greece avoid default.
U.S. retail sales jump 0.8% in July
Reversing three months of decline, U.S. retail sales jumped 0.8% in July, pointing to a stronger third quarter and indicating that a slowdown in the second quarter may have been temporary. However, signals were mixed in two other indicators, with business inventories rising in June as companies anticipated higher consumer demand but with business sales dropping for the third month in a row.
Market Activities
INTERNATIONAL MARKETS OVERVIEW
INTERNATIONAL MARKETS OVERVIEW
Stronger-than-expected German growth figures and a surprising jump in U.S. retail sales helped lift European stocks Tuesday, with the Stoxx Europe 600 index adding 0.7%. The same data also provided an early impetus for U.S. shares, but the market eased later in the day and the S&P 500 ended a fraction of a point lower in light trading. Here is a continuously updated list of global stock indexes.
Economic Trends & Outlook
Fears grow that Japanese recovery may be sidetracked
Although the Japanese government is predicting continued recovery over the second half of the year, new concerns are being raised that the imperiled European economy and, domestically, the end of subsidies for eco-friendly vehicles will contribute to further slowing in the current quarter. In addition, poor economic conditions could work to delay implementation of a tax increase just passed into law.
China's 2012 growth is now pegged at 8.0% by Morgan Stanley
An absence of economic stimulus and faltering external demand were cited by Morgan Stanley as it cut its growth forecast for China to 8.0% this year and 8.6% in 2013. Morgan does see an easing policy in the next one to two months, as well as a quarter-point interest-rate cut before the end of the year.
China may be preparing sharper clampdown on property market
With inspection teams back in Beijing and preparing their reports on how well provincial governments have acted to restrain their property markets, expectations are growing that further curbs will be introduced. Some governments have already been warned that they haven't done enough to implement past measures.
South Korea posts 6th month of trade surplus
South Korea's trade surplus in July was down a sharp 40% from the previous month but remained strongly positive at $2.76 billion, according to the Korea Customs Service. July's was the sixth consecutive month of surplus, although exports and imports both declined. Separately, Nomura predicts lower inflation in South Korea for the second half.
National Australia Bank predicts a rate boost in 2013
An increase in interest rates may be in store for the coming year in Australia, according to National Australia Bank, which changed its forecast to become the first major bank predicting a boost. If the central bank does raise its rate, it will mark the first increase since November 2010.
Indonesia consumer confidence, outlook hard to beat
Indonesia's consumer confidence as measured by KADIN-Roy Morgan at 150.5 points in July topped by a wide margin comparable measures in every other Group of 20 country. "While global gloom is taking its toll on China and India, Indonesia continues to swim against the tide," said KADIN Chairman Suryo Sulisto. The survey also found that 79% of Indonesians are optimistic about the country's economy over the next 12 months.
Capital Markets & Financial Products
EU calls for more Indian "stability" to pull in investment
Noting that EU investment to date in China, Russia and other countries far surpasses investment in India, a visiting EU delegation called for more "stability and predictability" in the Indian market. "Though economic relations between India and EU have been multi-dimensional and have expanded over time, they are far below the potential," commented delegate Joao Cravinho. The EU and India are negotiating a trade accord that would lower duties and spur investment.
China's yuan funds for foreign exchange decline amid global slowdown
Reduced trade and foreign direct investment contributed to a decline in China's yuan funds outstanding for foreign exchange in July. The total of 25.66 trillion yuan was down nearly 3.82 billion yuan from the previous month, the central bank said. The drop also suggests a strong outflow of foreign capital amid the global debt crisis and slowing economy.